Document is current
Any future updates will be listed below
-
Authors
Suttorp, Meinolf
Schulze, Philipp
Glauche, Ingmar https://orcid.org/0000-0002-2524-1199
Göhring, Gudrun
von Neuhoff, Nils
Metzler, Markus
Sedlacek, Petr
de Bont, Eveline S. J. M.
Balduzzi, Adriana
Lausen, Birgitte
Aleinikova, Olga
Sufliarska, Sabina
Henze, Günter
Strauss, Gabriele
Eggert, Angelika
Kremens, Bernhard
Groll, Andreas H.
Berthold, Frank
Klein, Christoph https://orcid.org/0000-0003-0956-0445
Groß-Wieltsch, Ute
Sykora, Karl Walter
Borkhardt, Arndt https://orcid.org/0000-0002-6121-4737
Kulozik, Andreas E. https://orcid.org/0000-0003-1953-0848
Schrappe, Martin
Nowasz, Christina
Krumbholz, Manuela
Tauer, Josephine T.
Claviez, Alexander
Harbott, Jochen
Kreipe, Hans H.
Schlegelberger, Brigitte
Thiede, Christian
- License Information
-
More Information
Article History
Received: 10 November 2017
Revised: 26 April 2018
Accepted: 1 May 2018
First Online: 20 June 2018
Compliance with ethical standards
:
: IG received research support (Institutional) and reimbursement for attending symposia from Bristol-Myers-Squibb. HHK received research support (Institutional) from Roche Pharma, and coverage of other expenses by Amgen, Astra Zeneca, Genomic Health, Lilly, and Roche Pharma. BS received fees for advisory board consultations (PARP inhibitors, not related to this trial) from Astra Zeneca. MSch received recent research support (Institutional) from Novartis in the time period from 2004 to 2012. MS received research support (Institutional) from Novartis and reimbursement for attending symposia organized by Bristol-Myers-Squibb, Novartis, and Pfizer. CT received research support (Institutional) from Bayer, Novartis, and Roche and is employed presently as CEO by AgenDix GmbH. The remaining authors declare that they have no conflict of interest. Neither Novartis nor any other pharmaceutical company was permitted prior insight to the results of trial CML-Paed II. Apart from the authors nobody participated in writing of the manuscript.
